NCT03723785View on ClinicalTrials.gov

A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney Problems

PHASE1CompletedINTERVENTIONAL

Enrollment

58

Participants

Timeline

Start Date

November 9, 2018

Primary Completion Date

September 6, 2019

Study Completion Date

September 6, 2019

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin icodec

Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1

Trial Locations (1)

10117

Charité Research Organisation GmbH, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY

NCT03723785 - A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney Problems | Biotech Hunter | Biotech Hunter